Evidence map›Paper›PMID 35836271›Full record

ArticleCancer imaging : the official publication of the International Cancer Imaging Society2022

Pretreatment visceral metastases in castration resistant metastatic prostate cancer: role in prediction versus actual site of disease progression.

Kathleen Ruchalski, Hyun J Kim, Michael Douek, Steven Raman, Maitraya Patel, Victor Sai, Antonio Gutierrez, Benjamin Levine, Cheryce Fischer, Martin Allen-Auerbach and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Histologically Confirmed Testicular Metastasis Revealed by [Diagnostics (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Kathleen RuchalskiDepartment of Radiological Sciences, UCLA, Los Angeles, CA, USA. kruchalski@mednet.ucla.edu.ORCID http://orcid.org/0000-0001-7988-8484
Hyun J KimDepartment of Radiological Sciences, UCLA, Los Angeles, CA, USA.
Michael DouekDepartment of Radiological Sciences, UCLA, Los Angeles, CA, USA.
Steven RamanDepartment of Radiological Sciences, UCLA, Los Angeles, CA, USA.
Maitraya PatelDepartment of Radiological Sciences, UCLA, Los Angeles, CA, USA.
Victor SaiDepartment of Radiological Sciences, UCLA, Los Angeles, CA, USA.
Antonio GutierrezDepartment of Radiological Sciences, UCLA, Los Angeles, CA, USA.
Benjamin LevineDepartment of Radiological Sciences, UCLA, Los Angeles, CA, USA.
Cheryce FischerDepartment of Radiological Sciences, UCLA, Los Angeles, CA, USA.
Martin Allen-AuerbachAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA.
Pawan GuptaAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA.
Heidi CoyUCLA Center for Computer Vision and Imaging Biomarkers, Los Angeles, CA, USA.
Bianca VillegasUCLA Center for Computer Vision and Imaging Biomarkers, Los Angeles, CA, USA.
Matthew BrownDepartment of Radiological Sciences, UCLA, Los Angeles, CA, USA.
Jonathan GoldinDepartment of Radiological Sciences, UCLA, Los Angeles, CA, USA.
University of California, Los Angeles · US

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
NCI NIH HHS P50 CA211015
6 · The paper itself

Abstract

backgroundTo evaluate the anatomic site(s) of initial disease progression in patients with castration resistant metastatic prostate cancer (mCRPC) in the presence or absence of pre-treatment visceral metastases while on systemic therapy.

methodsThis is a retrospective cohort study of mCRPC patients who have baseline and at least one follow up bone scan and CT chest, abdomen and pelvis (CAP). Disease progression was determined by RECIST and/or ≥ 30% increase in automated bone scan lesion area score. Kaplan-Meier plot was used to estimate the median progression free survival and log-rank tests were used to compare anatomic sites.

resultsOf 203 patients, 61 (30%) had pre-treatment visceral metastases. Patients with baseline visceral disease were 1.5 times more likely to develop disease progression (HR = 1.53; 95% CI, 1.03-2.26). Disease progression was a result of worsening bone scan disease (42% (16/38)) versus visceral (32% (12/38)) or lymph node disease (3% (1/38)) by CT or a combination thereof (23% (9/38)). Median time to progression (TTP) did not differ by anatomic location of initial progression (p = 0.86). Development of new lesions occurred in 50% of those visceral patients with soft tissue only progression and was associated with a significantly longer TTP (3.1 months (2.8-4.3 months) than those with worsening of pre-existing lesions (1.8 months (1.6-2.7 months); p = 0.04.

conclusionsPatients with pre-treatment visceral metastases in mCRPC are more likely to experience disease progression of bone disease with the initial anatomic site of progression similar to those without baseline visceral involvement.

Indexed as

Prostatic Neoplasms, Castration-ResistantCastrationDisease ProgressionHumansMaleRetrospective StudiesTomography, X-Ray ComputedTreatment OutcomeDisease progressionProstate cancerRECISTVisceral metastases

Identifiers

PMID35836271
PMCPMC9281063
OpenAlexW4285386092

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.